TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kymera Therapeutics (KYMR – Research Report), Nektar Therapeutics (NKTR – Rese ...

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

Kymera Therapeutics announces $250.8 million public offering of common stock and pre-funded warrants to advance its biopharmaceutical programs.